Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction

Cancer Cell

Volumn 3, Issue 5, 2003, Pages 431-437

  Ho, William Y ^a   Blattman, Joseph N ^a   Dossett, Michelle L ^a   Yee, Cassian ^a   Greenberg, Philip D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 15; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNITY; BINDING AFFINITY; BIOENGINEERING; CANCER; CARCINOGENESIS; CELL MIGRATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; DESTRUCTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL TECHNOLOGY; MOLECULAR CLONING; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; T LYMPHOCYTE; TARGET CELL; ANIMAL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; BIOLOGICAL MODEL; IMMUNOLOGY; METHODOLOGY; NEOPLASM; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; CELL SURVIVAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; T-LYMPHOCYTES;

EID: 1542404892     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00113-2     Document Type: Review

References (59)

1. Appay V., Dunbar P.R., Callan M., Klenerman P., Gillespie G.M., Papagno L., Ogg G.S., King A., Lechner F., Spina C.A., et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:2002;379-385.
2. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 285:1999;727-729.
3. Becker C., Pohla H., Frankenberger B., Schuler T., Assenmacher M., Schendel D.J., Blankenstein T. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat. Med. 7:2001;1159-1162.
4. Blattman J.N., Grayson J.M., Wherry E.J., Kaech S.M., Smith K.A., Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:2003;540-547.
5. Boon T., Cerottini J.C., Van den Eynde B., van der Bruggen P., Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:1994;337-365.
6. Bos J.L. The ras gene family and human carcinogenesis. Mutat. Res. 195:1988;255-271.
7. Brentjens R.J., Latouche J.B., Santos E., Marti F., Gong M.C., Lyddane C., King P.D., Larson S., Weiss M., Riviere I., Sadelain M. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9:2003;279-286.
8. Bulfone-Pau S.S., Bulanova E., Pohl T., Budagian V., Durkop H., Ruckert R., Kunzendorf U., Paus R., Krause H. Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain. FASEB J. 13:1999;1575-1585.
9. Chames P., Willemsen R.A., Rojas G., Dieckmann D., Rem L., Schuler G., Bolhuis R.L., Hoogenboom H.R. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. 169:2002;1110-1118.
10. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., Old L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA. 94:1997;1914-1918.
11. Cheng L.E., Ohlen C., Nelson B.H., Greenberg P.D. Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc. Natl. Acad. Sci. USA. 99:2002;3001-3006.
12. Chiang Y.J., Kole H.K., Brown K., Naramura M., Fukuhara S., Hu R.J., Jang I.K., Gutkind J.S., Shevach E., Gu H. Cbl-b regulates the CD28 dependence of T-cell activation. Nature. 403:2000;216-220.
13. Clay T.M., Custer M.C., Sachs J., Hwu P., Rosenberg S.A., Nishimura M.I. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163:1999;507-513.
14. Cooper L.J., Kalos M., Lewinsohn D.A., Riddell S.R., Greenberg P.D. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74:2000;8207-8212.
15. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 286:2002a;850-854.
16. Dudley M.E., Wunderlich J.R., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R.M., Marincola F.M., Leitman S.F., Seipp C.A., et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25:2002b;243-251.
17. Dummer W., Niethammer A.G., Baccala R., Lawson B.R., Wagner N., Reisfeld R.A., Theofilopoulos A.N. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110:2002;185-192.
18. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA. 90:1993;720-724.
19. Garlie N.K., LeFever A.V., Siebenlist R.E., Levine B.L., June C.H., Lum L.G. T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J. Immunother. 22:1999;336-345.
20. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 36:1984;93-99.
21. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA. 96:1999;6879-6884.
22. Holler P.D., Holman P.O., Shusta E.V., O'Herrin S., Wittrup K.D., Kranz D.M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA. 97:2000;5387-5392.
23. Holler P.D., Chlewicki L.K., Kranz D.M. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4:2003;55-62.
24. Husson H., Freedman A.S., Cardoso A.A., Schultze J., Munoz O., Strola G., Kutok J., Carideo E.G., De Beaumont R., Caligaris-Cappio F., Ghia P. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br. J. Haematol. 119:2002;492-495.
25. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 421:2003;852-856.
26. Kalergis A.M., Boucheron N., Doucey M.A., Palmieri E., Goyarts E.C., Vegh Z., Luescher I.F., Nathenson S.G. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. 2:2001;229-234.
27. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Rivoltini L., Topalian S.L., Miki T., Rosenberg S.A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA. 91:1994;3515-3519.
28. Keenan R.D., Ainsworth J., Khan N., Bruton R., Cobbold M., Assenmacher M., Milligan D.W., Moss P.A. Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br. J. Haematol. 115:2001;428-434.
29. Kershaw M.H., Wang G., Westwood J.A., Pachynski R.K., Tiffany H.L., Marincola F.M., Wang E., Young H.A., Murphy P.M., Hwu P. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13:2002;1971-1980.
30. Kessels H.W., van Den Boom M.D., Spits H., Hooijberg E., Schumacher T.N. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. USA. 97:2000;14578-14583.
31. Kuriyama M., Loor R., Wang M.C., Lee C., Killian C.S., Papsidero L.D., Inaji H., Nishiura T., Slack N.H., Murphy G.P., Chu T.M. Prostatic acid phosphatase and prostate-specific antigen in prostate cancer. Int. Adv. Surg. Oncol. 5:1982;29-49.
32. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., Johnson D., Swetter S., Thompson J., Greenberg P.D., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:1999;677-685.
33. Lu J., Giuntoli R.L., Omiya R. 2nd, Kobayashi H., Kennedy R., Celis E. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 8:2002;3877-3884.
34. Lynch D.H., Miller R.E. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J. Exp. Med. 179:1994;31-42.
35. Marshall E. Gene therapy. Second child in French trial is found to have leukemia. Science. 299:2003;320.
36. Maus M.V., Thomas A.K., Leonard D.G., Allman D., Addya K., Schlienger K., Riley J.L., June C.H. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20:2002;143-148.
37. Niedobitek G., Meru N., Delecluse H.J. Epstein-Barr virus infection and human malignancies. Int. J. Exp. Pathol. 82:2001;149-170.
38. Ohlen C., Kalos M., Cheng L.E., Shur A.C., Hong D.J., Carson B.D., Kokot N.C., Lerner C.G., Sather B.D., Huseby E.S., Greenberg P.D. CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med. 195:2002;1407-1418.
39. Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., Nagler A., Ben-Hur H., Many A., Shultz L., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 283:1999;845-848.
40. Pfreundschuh M. Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer Chemother. Pharmacol. 46:2000;S3-S7.
41. Riddell S.R., Greenberg P.D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods. 128:1990;189-201.
42. Riddell S.R., Elliott M., Lewinsohn D.A., Gilbert M.J., Wilson L., Manley S.A., Lupton S.D., Overell R.W., Reynolds T.C., Corey L., Greenberg P.D. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2:1996;216-223.
43. Roberts M.R., Qin L., Zhang D., Smith D.H., Tran A.C., Dull T.J., Groopman J.E., Capon D.J., Byrn R.A., Finer M.H. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood. 84:1994;2878-2889.
44. Rooney C.M., Smith C.A., Ng C.Y., Loftin S.K., Sixbey J.W., Gan Y., Srivastava D.K., Bowman L.C., Krance R.A., Brenner M.K., Heslop H.E. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 92:1998;1549-1555.
45. Sadelain M., Riviere I., Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 3:2003;35-45.
46. Springer C.J., Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J. Clin. Invest. 105:2000;1161-1167.
47. Stanislawski T., Voss R.H., Lotz C., Sadovnikova E., Willemsen R.A., Kuball J., Ruppert T., Bolhuis R.L., Melief C.J., Huber C., et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2:2001;962-970.
48. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:2001;823-832.
49. Thomis D.C., Marktel S., Bonini C., Traversari C., Gilman M., Bordignon C., Clackson T. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood. 97:2001;1249-1257.
50. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den Driesch P., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocytederived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1999;1669-1678.
51. van de Vijver M., van de Bersselaar R., Devilee P., Cornelisse C., Peterse J., Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell. Biol. 7:1987;2019-2023.
52. Verzeletti S., Bonini C., Marktel S., Nobili N., Ciceri F., Traversari C., Bordignon C. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum. Gene Ther. 9:1998;2243-2251.
53. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1995;1038-1044.
54. Warren E.H., Greenberg P.D., Riddell S.R. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 91:1998;2197-2207.
55. Yamagami T., Sugiyama H., Inoue K., Ogawa H., Tatekawa T., Hirata M., Kudoh T., Akiyama T., Murakami A., Maekawa T. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 87:1996;2878-2884.
56. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. 192:2000;1637-1644.
57. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA. 99:2002;16168-16173.
58. Zheng L., Trageser C.L., Willerford D.M., Lenardo M.J. T cell growth cytokines cause the superinduction of molecules mediating antigeninduced T lymphocyte death. J. Immunol. 160:1998;763-769.
59. zur Hausen H. Papillomaviruses in human cancers. Proc. Assoc. Am. Physicians. 111:1999;581-587.